Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.
Deparment of Rheumatology and Immunology, China Medical University Hospital, Taichung, Taiwan.
RMD Open. 2022 Aug;8(2). doi: 10.1136/rmdopen-2022-002343.
To examine the risk and risk factors of mortality in patients with rheumatoid arthritis (RA) with interstitial lung disease (ILD).
Using the 1997-2013 Taiwanese National Health Insurance Research Database, we identified 32 289 incident patients with RA by using International Classification of Diseases, Ninth Revision codes from 2001 to 2013, and 214 patients developed ILD subsequently. We matched (1:10) RA-ILD with controls for sex, age, time of ILD diagnosis and disease duration. In addition, we conducted propensity score matching (PSM) (1:1) for selected comorbidities to choose RA-ILD patients and controls. Using the Cox proportional hazard model, we estimated the association of mortality with ILD for the two matched populations and assessed factors associated with mortality among 214 RA-ILD patients, shown as adjusted HRs (aHRs) with 95% CIs.
In the populations selected before and after PSM, we included 164 and 155 patients with RA-ILD and 1640 and 155 controls, respectively. ILD was associated with mortality in the population before PSM (aHR, 1.73; 95% CI 1.19 to 2.52) and in the PSM population (HR 4.38; 95% CI 2.03 to 9.43). Among 214 patients with RA-ILD, age (aHR 1.04; 95% CI 1.03 to 1.08), chronic obstructive pulmonary disease (COPD) (aHR 2.12; 95% CI 1.25 to 3.58), diabetes mellitus (DM) with end-organ damage and corticosteroid dose (prednisolone equivalent, mg/day) (aHR 1.09; 95% CI 1.07 to 1.11) were associated with mortality in RA-ILD.
This population-based cohort study showed that ILD was associated with risk of mortality in patients with RA, and risk factors associated with mortality in patients with RA-ILD included age, COPD, DM with end-organ damage and average daily prednisolone dose.
探讨类风湿关节炎(RA)合并间质性肺疾病(ILD)患者的死亡风险和危险因素。
利用 1997-2013 年台湾全民健康保险研究数据库,我们采用国际疾病分类第 9 版代码从 2001 年至 2013 年识别了 32289 例新发 RA 患者,其中 214 例随后发展为ILD。我们对性别、年龄、ILD 诊断时间和疾病持续时间进行 1:10 的匹配,以选择 RA-ILD 患者和对照组。此外,我们还进行了倾向评分匹配(PSM)(1:1)以选择具有选定合并症的 RA-ILD 患者和对照组。采用 Cox 比例风险模型,我们分别对两组匹配人群进行死亡率与ILD 相关性的估计,并评估了 214 例 RA-ILD 患者死亡率相关的因素,结果表示为调整后的 HR(aHR)及其 95%CI。
在 PSM 前后选择的人群中,我们分别纳入了 164 例 RA-ILD 患者和 1640 例对照组以及 155 例 RA-ILD 患者和 155 例对照组。ILD 在 PSM 前人群(aHR,1.73;95%CI 1.19 至 2.52)和 PSM 人群(HR 4.38;95%CI 2.03 至 9.43)中与死亡率相关。在 214 例 RA-ILD 患者中,年龄(aHR 1.04;95%CI 1.03 至 1.08)、慢性阻塞性肺疾病(COPD)(aHR 2.12;95%CI 1.25 至 3.58)、糖尿病(DM)伴终末器官损害和皮质类固醇剂量(泼尼松等效剂量,mg/天)(aHR 1.09;95%CI 1.07 至 1.11)与 RA-ILD 患者的死亡率相关。
本基于人群的队列研究表明,ILD 与 RA 患者的死亡风险相关,RA-ILD 患者死亡的相关危险因素包括年龄、COPD、DM 伴终末器官损害和平均每日泼尼松剂量。